Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
65°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by 89bio, Inc.
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Appoints Francis Sarena as Chief Operating Officer
August 07, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
August 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
May 22, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
May 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
May 02, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
April 17, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
March 27, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
March 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
February 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 12, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
December 06, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
December 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
November 27, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
November 21, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
November 12, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
November 08, 2023
From
89bio, Inc.
Via
GlobeNewswire
Tickers
ETNB
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.